WallStSmart

Repro Med Systems Inc (KRMD)vsWest Pharmaceutical Services Inc (WST)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

West Pharmaceutical Services Inc generates 7275% more annual revenue ($3.33B vs $45.11M). WST leads profitability with a 17.0% profit margin vs -4.0%. WST earns a higher WallStSmart Score of 61/100 (C+).

KRMD

Avoid

26

out of 100

Grade: F

Growth: 6.0Profit: 3.0Value: 5.0Quality: 6.0
Piotroski: 3/9Altman Z: 0.98

WST

Buy

61

out of 100

Grade: C+

Growth: 6.0Profit: 8.0Value: 2.7Quality: 8.5
Piotroski: 4/9Altman Z: 4.73
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for KRMD.

WSTSignificantly Overvalued (-46.2%)

Margin of Safety

-46.2%

Fair Value

$168.33

Current Price

$346.23

$177.90 premium

UndervaluedFair: $168.33Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

KRMD2 strengths · Avg: 8.5/10
Debt/EquityHealth
0.189/10

Conservative balance sheet, low leverage

Revenue GrowthGrowth
18.2%8/10

18.2% revenue growth

WST3 strengths · Avg: 9.0/10
Altman Z-ScoreHealth
4.7310/10

Safe zone — low bankruptcy risk

Debt/EquityHealth
0.109/10

Conservative balance sheet, low leverage

Operating MarginProfitability
22.5%8/10

Strong operational efficiency at 22.5%

Areas to Watch

KRMD4 concerns · Avg: 3.0/10
Price/BookValuation
8.1x4/10

Trading at 8.1x book value

Market CapQuality
$147.90M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Return on EquityProfitability
-13.5%2/10

ROE of -13.5% — below average capital efficiency

WST3 concerns · Avg: 2.7/10
Price/BookValuation
8.2x4/10

Trading at 8.2x book value

PEG RatioValuation
2.672/10

Expensive relative to growth rate

P/E RatioValuation
43.5x2/10

Premium valuation, high expectations priced in

Comparative Analysis Report

WallStSmart Research

Bull Case : KRMD

The strongest argument for KRMD centers on Debt/Equity, Revenue Growth. Revenue growth of 18.2% demonstrates continued momentum.

Bull Case : WST

The strongest argument for WST centers on Altman Z-Score, Debt/Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 22.5%. Revenue growth of 13.8% demonstrates continued momentum.

Bear Case : KRMD

The primary concerns for KRMD are Price/Book, Market Cap, Piotroski F-Score.

Bear Case : WST

The primary concerns for WST are Price/Book, PEG Ratio, P/E Ratio. A P/E of 43.5x leaves little room for execution misses.

Key Dynamics to Monitor

KRMD profiles as a growth stock while WST is a mature play — different risk/reward profiles.

WST carries more volatility with a beta of 1.14 — expect wider price swings.

KRMD is growing revenue faster at 18.2% — sustainability is the question.

WST generates stronger free cash flow (81M), providing more financial flexibility.

Bottom Line

WST scores higher overall (61/100 vs 26/100), backed by strong 17.0% margins and 13.8% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Repro Med Systems Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Repro Med Systems, Inc., doing business as KORU Medical Systems, designs, manufactures, and markets portable medical devices primarily for the ambulatory infusion market in the United States and internationally. The company is headquartered in Chester, New York.

West Pharmaceutical Services Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

West Pharmaceutical Services, Inc. is a designer and manufacturer of injectable pharmaceutical packaging and delivery systems. The company is headquartered in Exton, Pennsylvania.

Want to dig deeper into these stocks?